http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-577394-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4e092ba7c0b4f2beba27b6420c0bd2ce |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-34 |
| filingDate | 2007-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abdb54c692ecda4b6f44a7d871965f92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2687928bc62beaf28d21e4129a361934 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccd2c8d5f634e02c33b2099571348f31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f937e2fd70b5bee90796e03d305aee3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59993daea816f7546cb81e7b57a9f5ce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cc9ca0bf7a6a06102e372a8598f870d |
| publicationDate | 2012-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-577394-A |
| titleOfInvention | Method of use of epiregulin protein and nucleic acid encoding the same in inflammatory conditions |
| abstract | Disclosed is a method for predicting the response of a patient to a drug employed in the treatment of an inflammatory condition in the patient, the method comprising: measuring the level of epiregulin gene expression in a blood sample from the patient to whom the drug has been administered; correlating the level of epiregulin gene expression in the patient's blood sample with the response to the treatment of the inflammatory condition, wherein elevated epiregulin level is indicative of positive response to the drug; and predicting the response of a patient to the drug employed in the treatment of the inflammatory condition. Further disclosed is a method of monitoring drug response in a patient receiving treatment for an inflammatory condition with an anti-inflammatory compound, the method comprising: measuring the level of epiregulin gene expression in a blood or serum sample from the patient to whom the anti-inflammatory compound has been administered; correlating the level of epiregulin gene expression in the patient's blood or serum sample with the patients response to the anti-inflammatory compound, wherein elevated epiregulin level is indicative of positive response to the anti-inflammatory compound; and monitoring drug response in the patient receiving treatment for inflammatory condition with the anti-inflammatory compound. |
| priorityDate | 2006-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 124.